SUPPLEMENTARY MATERIAL
Supplementary Table 1. Prioritization of symptoms, split by physician specialty
Rheumatologist Dermatologist Joint-only Joint & skin Joint-only Joint & skin Given the choice of only one,
would you rather be free of your…?
Skin symptoms Joint symptoms
N=181
36 (19.9) 145 (80.1)
N=292
122 (41.8) 170 (58.2)
N=193
99 (51.3) 94 (48.7)
N=484
187 (38.6) 297 (61.4) Do you experience anxiety and/or
depression as a direct result of your PsA?
Yes No
N=107
39 (36.4) 68 (63.6)
N=144
47 (32.6) 97 (67.4)
N=77
30 (39.0) 47 (61.0)
N=249
121 (48.6) 128 (51.4) Which of the following is the cause
of your anxiety and/or depression?
Skin symptoms Joint symptoms Both skin & joint symptoms
N=36
- 18 (50.0) 18 (50.0)
N=45
7 (15.6) 8 (17.8) 30 (66.7)
N=30
2 (6.7) 9 (30.0) 19 (63.3)
N=118
12 (10.2) 30 (25.4) 76 (64.4)
Supplementary Table 2. Clinical characteristics and patient reported outcomes in patients with joint and skin PsA stratified according to physician-reported skin severity – Rheumatologist-managed patients
Parameter Overall Mild Moderate Severe
n % 643 457 165 21
Overall severity, n (%)
Mild 418 (65.0) 378 (82.7) 35 (21.2) 5 (23.8)
Moderate 197 (30.6) 73 (16.0) 119 (72.1) 5 (23.8)
Severe 28 (4.4) 6 (1.3) 11 (6.7) 11 (52.4)
Joints severity, n (%)
Mild 417 (64.9) 368 (80.5) 44 (26.7) 5 (23.8)
Moderate 200 (31.1) 80 (17.5) 111 (67.3) 9 (42.9)
Severe 26 (4.0) 9 (2.0) 10 (6.1) 7 (33.3)
Disease Status, n (%)
Improving 218 (33.9) 166 (36.3) 48 (29.1) 4 (19.0)
Stable 325 (50.5) 252 (55.1) 68 (41.2) 5 (23.8)
Unstable 64 (10.0) 22 (4.8) 37 (22.4) 5 (23.8)
Deteriorating slowly 27 (4.2) 14 (3.1) 9 (5.5) 4 (19.0)
Deteriorating rapidly 9 (1.4) 3 (0.7) 3 (1.8) 3 (14.3)
Does patient experience flares? n (%)
n 632 451 161 20
Yes, currently experiencing a flare 58 (9.2) 22 (4.9) 27 (16.8) 9 (45.0)
Yes, within the last 12 months but not currently 155 (24.5) 105 (23.3) 47 (29.2) 3 (15.0)
Yes, but not within the last 12 months 168 (26.6) 134 (29.7) 31 (19.3) 3 (15.0)
Pain (1‒10)
Mean (SD) 3.28 (1.82) 2.81 (1.53) 4.27 (1.87) 5.71 (2.24)
EQ-5D utility score
n 314 232 78 4
Mean (SD) 0.77 (0.19) 0.79 (0.18) 0.71 (0.21) 0.80 (0.05)
Median (IQR) 0.79 (0.18) 0.81 (0.18) 0.74 (0.18) 0.82 (0.10)
EQ-5D VAS score
Mean (SD) 69.74 (21.08) 71.51 (21.59) 64.06 (18.83) 73.00 (16.81)
Median (IQR) 74.50 (25.00) 75.00 (30.00) 70.00 (21.00) 75.00 (25.00)
HAQ Disability index
n 304 227 73 4
Mean (SD) 0.64 (0.63) 0.59 (0.60) 0.81 (0.69) 0.35 (0.38)
Median (IQR) 0.50 (1.00) 0.38 (1.00) 0.75 (1.25) 0.26 (0.71)
WPAI: Percent work time missed due to problem
n 132 96 35 1
Mean (SD) 5.01 (18.46) 5.75 (19.10) 3.14 (16.94) -
Median (IQR) - - - -
WPAI: Percent impairment while working due to problem
n 139 102 36 1
Mean (SD) 25.18 (19.87) 22.84 (20.56) 32.22 (16.23) 10.00 (0)
Median (IQR) 20.00 (20.00) 20.00 (20.00) 30.00 (20.00) 10.00 (0)
WPAI: Percent overall work impairment due to problem
n 128 93 34 1
Mean (SD) 26.17 (20.08) 24.33 (21.05) 31.68 (16.38) 10.00 (0)
Median (IQR) 20.00 (20.00) 20.00 (20.00) 30.00 (20.00) 10.00 (0)
WPAI: Percent activity impairment due to problem
n 311 232 75 4
Mean (SD) 32.73 (24.12) 29.66 (23.83) 41.73 (22.14) 42.50 (37.75)
Median (IQR) 30.00 (40.00) 20.00 (30.00) 40.00 (20.00) 40.00 (67.50)
PsAID12 score (0‒10)
n 233 169 60 4
Mean (SD) 3.03 (2.02) 2.68 (1.97) 4.01 (1.87) 3.09 (1.53)
Median (IQR) 2.70 (2.48) 2.15 (2.40) 3.60 (2.21) 3.15 (2.79)
Supplementary Table 3. Clinical characteristics and patient reported outcomes in patients with joint and skin PsA stratified according to
physician-reported skin severity – Dermatologist- managed patientsParameter
Overall Mild Moderate
Severe
n % 1103 786 274 43
Overall severity, n (%)
Mild 790 (71.6) 691 (87.9) 89 (32.5) 10 (23.3)
Moderate 278 (25.2) 83 (10.6) 176 (64.2) 19 (44.2)
Severe 35 (3.2) 12 (1.5) 9 (3.3) 14 (32.6)
Joints severity, n (%)
Mild 806 (73.1) 678 (86.3) 117 (42.7) 11 (25.6)
Moderate 265 (24.0) 93 (11.8) 147 (53.6) 25 (58.1)
Severe 32 (2.9) 15 (1.9) 10 (3.6) 7 (16.3)
Disease Status, n (%)
Improving 411 (37.3) 316 (40.2) 94 (34.3) 1 (2.3)
Stable 542 (49.1) 422 (53.7) 108 (39.4) 12 (27.9)
Unstable 90 (8.2) 31 (3.9) 44 (16.1) 15 (34.9)
Deteriorating slowly 49 (4.4) 16 (2.0) 25 (9.1) 8 (18.6)
Deteriorating rapidly 11 (1.0) 1 (0.1) 3 (1.1) 7 (16.3)
Does patient experience flares? n (%)
n 1081 773 267 41
Yes, currently experiencing a flare 92 (8.5) 30 (3.9) 43 (16.1) 19 (46.3)
Yes, within the last 12 months but not currently 293 (27.1) 198 (25.6) 88 (33.0) 7 (17.1)
Yes, but not within the last 12 months 301 (27.8) 238 (30.8) 60 (22.5) 3 (7.3)
Pain (1‒10)
Mean (SD) 2.97 (1.76) 2.53 (1.46) 3.85 (1.82) 5.35 (2.32)
EQ-5D utility score
n 522 355 144 23
Mean (SD) 0.80 (0.16) 0.83 (0.15) 0.75 (0.15) 0.70 (0.27)
Median (IQR) 0.82 (0.18) 0.83 (0.24) 0.76 (0.14) 0.73 (0.30)
EQ-5D VAS score
Mean (SD) 73.38 (17.42) 76.15 (16.81) 68.87 (16.45) 59.26 920.39)
Median (IQR) 75.00 (20.00) 80.00 (20.00) 70.00 (20.00) 65.00 (25.00)
HAQ Disability index
n 503 340 142 21
Mean (SD) 0.53 (0.57) 0.43 (0.52) 0.73 (0.59) 0.73 (0.67)
Median (IQR) 0.38 (0.88) 0.25 (0.75) 0.69 (0.91) 0.43 (1.31)
WPAI: Percent work time missed due to problem
n 253 166 75 12
Mean (SD) 4.52 (14.79) 2.19 (10.27) 9.66 (21.44) 4.70 (8.66)
Median (IQR) 0 (0) 0 (0) 0 (10.26) 0 (10.71)
WPAI: Percent impairment while working due to problem
n 276 186 78 12
Mean (SD) 22.25 (18.19) 17.90 (14.20) 29.10 (20.52) 45.00 (26.80)
Median (IQR) 20.00 (20.00) 20.00 (20.00) 20.00 (20.00) 40.00 (45.00)
WPAI: Percent overall work impairment due to problem
n 249 165 72 12
Mean (SD) 25.24 (20.62) 19.67 (16.02) 34.46 (23.23) 46.40 (27.71)
Median (IQR) 20.00 (20.00) 20.00 (20.00) 30.00 (33.21) 40.00 (45.13)
WPAI: Percent activity impairment due to problem
n 513 349 144 20
Mean (SD) 28.19 (21.78) 24.21 (20.02) 34.79 (22.28) 50.00 (24.06)
Median (IQR) 20.00 (30.00) 20.00 (30.00) 30.00 (30.00) 50.00 (27.50)
PsAID12 score (0‒10)
n 437 288 127 22
Mean (SD) 2.85 (2.11) 2.35 (1.89) 3.56 (2.09) 5.16 (2.24)
Median (IQR) 2.50 (2.65) 1.90 (2.24) 3.30 (3.05) 5.08 (3.15)
Supplementary Figure 1. Anxiety and depression, patient-reported causes of burden of symptoms in patients with ‘joint-only’ and
‘joint and skin’ symptoms – Regional Results
42.6
33.3
40.6
34.1
54.0
55.6
57.4
66.7
59.4
65.9
46.0
No Yes 44.4
Do you experience anxiety and/or depression as a
direct result of your PsA?
5.6 15.1 0.0
7.4 5.3
33.3 22.6 48.3 33.3 36.8
61.1 62.4
51.7 59.3
57.9
Your skin symptoms Your joint symptoms Both your skin & joint symptoms
Which of the following is the
cause of your anxiety and/or depression?
55.8 33.6
30.4 33.9
41.3
41.7
44.2 66.4
69.6 66.1
58.7
58.3 Skin symptoms Joint symptoms
Given the choice of only one, would you rather
be completely free of your…?
No significant differences (p>0.001) were observed between patients with ‘joint-only’ and ‘joint and skin’ symptoms in response to the questions
‘Do you experience anxiety and/or depression as a direct result of your PsA’, ‘What is the cause of your anxiety and/or depression’ and ‘Given the choice of only one, would you rather be free of your skin or joint symptoms?’
North-America: US & Canada; EU5: France Germany, Italy, Spain, UK; APAC: Japan & Australia
Supplementary Table 4. Patient reported outcomes in overall population and patients with ‘joint only’ and ‘joint and skin’ PsA
– North America
Parameter Overall Joint-only Joint and skin p-value*
EQ-5D utility score
n 356 120 236 p<0.001
Mean (SD) 0.82 (0.14) 0.86 (0.14) 0.80 (0.13)
Median (IQR) 0.83 (0.75, 0.89) 0.86 (0.79, 1.00) 0.82 (0.74, 0.86) EQ-5D VAS
n 363 123 240 p<0.001
Mean (SD) 77.20 (16.84) 82.89 (14.76) 74.29 (17.12)
Median (IQR) 80.00 (70.0, 90.0) 87.00 (75.0, 94.0) 75.00 (65.0, 90.0) HAQ Disability Index
n 341 112 229 P=0.010
Mean (SD) 0.41 (055) 0.30 (0.50) 0.46 (0.56)
Median (IQR) 0.13 (0.00, 0.63) 0.00 (0.00, 0.38) 0.25 (0.00, 0.75) WPAI: Percent work time missed due to problem
n 225 71 154 p=0.031
Mean (SD) 4.05 (15.02) 7.22 (20.80) 2.59 (11.21)
Median (IQR) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00) WPAI: Percent impairment while working due to problem
n 229 74 155 p<0.001
Mean (SD) 19.48 (19.64) 12.30 (17.79) 22.90 (19.61)
Median (IQR) 20.00 (0.00, 30.00) 10.00 (0.00, 20.00) 20.00 (10.00, 30.00) WPAI: Percent overall work impairment due to problem
n 220 69 151 p=0.010
Mean (SD) 21.49 (21.54) 15.91 (22.33) 24.04 (20.75)
Median (IQR) 20.00 (0.00, 30.00) 10.00 (0.00, 20.00) 20.00 (10.00, 30.00) WPAI: Percent activity impairment due to problem
Mean (SD) 24.52 (22.73) 19.26 (21.84) 27.27 (22.74) Median (IQR) 20.00 (10.00, 30.00) 10.00 (0.00, 30.00) 20.00 (10.00, 40.00) PsAID12 score (0‒10)
n 343 115 228 p<0.001
Mean (SD) 2.47 (2.12) 1.70 (1.93) 2.85(2.11)
Median (IQR) 2.00 (0.75, 3.45) 1.05 (0.35, 2.30) 2.65 (1.18, 3.80)
*Student’s t test was used to compare outcomes from ‘joint-only’ with ‘joint and skin’ groups.
North America includes US & Canada
EQ-5D, EuroQol Five Dimension questionnaire; HAQ-DI, Health Assessment Questionnaire-Disability Index, IQR, interquartile range; PsAID12, Psoriatic Arthritis Impact of Disease questionnaire; SD, standard deviation; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.
Supplementary Table 5. Patient reported outcomes in overall population and patients with ‘joint only’ and ‘joint and skin’ PsA
– EU5 Results
Parameter Overall Joint-only Joint and skin p-value*
EQ-5D utility score
n 609 190 419 p<0.001
Mean (SD) 0.81 (0.19) 0.85 (0.18) 0.80 (0.18)
Median (IQR) 0.84 (0.74, 1.00) 0.91 (0.79, 1.00) 0.83 (0.73, 0.91) EQ-5D VAS
n 616 193 423 p<0.001
Mean (SD) 72.54 (18.92) 75.76 (17.49) 71.06 (19.38)
Median (IQR) 80.00 (60.0, 87.0) 80.00 (70.0, 90.0) 75.00 (60.0, 86.0) HAQ Disability Index
n 594 184 410 p<0.001
Mean (SD) 0.55 (0.59) 0.34 (0.48) 0.64 (0.61)
Median (IQR) 0.38 (0.00, 1.00) 0.13 (0.00, 0.63) 0.50 (0.00, 1.00) WPAI: Percent work time missed due to problem
n 296 88 208 p=0.711
Mean (SD) 5.91 (18.22) 5.30 (16.00) 6.16 (19.11)
Median (IQR) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
WPAI: Percent impairment while working due to problem
n 353 116 237 p<0.001
Mean (SD) 19.72 (17.64) 11.90 (14.68) 23.54 (17.73)
Median (IQR) 20.00 (10.00, 30.00) 10.00 (0.00, 20.00) 20.00 (10.00, 30.00) WPAI: Percent overall work impairment due to problem
n 290 87 203 p<0.001
Mean (SD) 23.94 (19.78) 17.42 (19.57) 26.73 (19.26)
Median (IQR) 20.00 (10.00, 30.00) 10.00 (0.00, 30.00) 25.85 (10.00, 33.04) WPAI: Percent activity impairment due to problem
n 605 190 415 p<0.001
Mean (SD) 28.35 (23.12) 20.53 (22.79) 31.93 (22.41)
Median (IQR) 20.00 (10.00, 40.00) 10.00 (0.00, 30.00) 30.00 (10.00, 50.00) PsAID12 score (0‒10)
n 600 189 411 p<0.001
Mean (SD) 2.57 (2.08) 1.68 (1.82) 2.98 (2.07)
Median (IQR) 2.05 (0.97, 3.70) 1.15 (0.20, 2.55) 2.60 (1.40, 4.05)
*Student’s t test was used to compare outcomes from ‘joint-only’ with ‘joint and skin’ groups.
EU5 includes France, Germany, Italy, Spain & UK.
EQ-5D, EuroQol Five Dimension questionnaire; HAQ-DI, Health Assessment Questionnaire-Disability Index, IQR, interquartile range; PsAID12, Psoriatic Arthritis Impact of Disease questionnaire; SD, standard deviation; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.
Supplementary Table 6. Patient reported outcomes in overall population and patients with ‘joint only’ and ‘joint and skin’ PsA
– APAC Results
Parameter Overall Joint-only Joint and skin p-value*
EQ-5D utility score
n 249 74 175 p=0.028
Mean (SD) 0.78 (0.19) 0.82 (0.19) 0.76 (0.19)
Median (IQR) 0.77 (0.67, 1.00) 0.82 (0.73, 1.00) 0.74 (0.64, 0.88) EQ-5D VAS
n 249 73 176 p=0.298
Mean (SD) 71.90 (20.25) 73.97 (19.95) 71.03 (20.36)
Median (IQR) 75.00 (61.00, 85.00) 80.00 (66.00, 90.00) 75.00 (60.00, 85.00) HAQ Disability Index
Mean (SD) 0.49 (0.58) 0.35 (0.57) 0.54 (0.58) Median (IQR) 0.25 (0.00, 0.88) 0.00 (0.00, 0.50) 0.38 (0.00, 0.88) WPAI: Percent work time missed due to problem
n 46 27 19 p=0.554
Mean (SD) 5.09 (13.75) 4.07 (13.59) 6.55 (14.22)
Median (IQR) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00) WPAI: Percent impairment while working due to problem
n 48 29 19 p=0.044
Mean (SD) 15.21 (20.83) 10.34 (14.76) 22.63 (26.42)
Median (IQR) 10.00 (0.00, 20.00) 0.00 (0.00, 20.00) 20.00 (0.00, 30.00) WPAI: Percent overall work impairment due to problem
n 46 27 19 p=0.100
Mean (SD) 18.92 (25.15) 13.79 (20.02) 26.20 (30.11)
Median (IQR) 10.00 (0.00, 30.00) 0.00 (0.00, 20.00) 20.00 (0.00, 52.00) WPAI: Percent activity impairment due to problem
n 247 74 173 p<0.001
Mean (SD) 25.43 (23.70) 17.16 (22.05) 28.96 (23.55)
Median (IQR) 20.00 (10.00, 40.00) 10.00 (0.00, 30.00) 20.00 (10.00, 40.00) PsAID12 score (0‒10)
n 67 39 28 p=0.063
Mean (SD) 1.81 (1.96) 1.43 (1.87) 2.33 (2.01)
Median (IQR) 1.30 (0.30, 2,60) 0.50 (0.10, 2.35) 1.95 (0.73, 3.10)
*Student’s t test was used to compare outcomes from ‘joint-only’ with ‘joint and skin’ groups.
APAC includes Japan & Australia
EQ-5D, EuroQol Five Dimension questionnaire; HAQ-DI, Health Assessment Questionnaire-Disability Index, IQR, interquartile range; PsAID12, Psoriatic Arthritis Impact of Disease questionnaire; SD, standard deviation; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.
